Cargando…
The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials
BACKGROUND: Migraine is the most common primary headache among children and adolescents. The aim of this meta-analysis was to evaluate the efficacy and safety of antiepileptic drugs in the prevention of pediatric migraine. METHODS: PubMed, Cochrane Library, EMBASE and Chinese National Knowledge Infr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349954/ https://www.ncbi.nlm.nih.gov/pubmed/34430426 http://dx.doi.org/10.21037/tp-20-478 |
_version_ | 1783735644578643968 |
---|---|
author | Jia, Guoyong Wang, Xingbang Lv, Hongbo Nonyane, Malebo Sarai Cheryl Hou, Haiguang Ma, Lin Shan, Peiyan Wu, Xinwei |
author_facet | Jia, Guoyong Wang, Xingbang Lv, Hongbo Nonyane, Malebo Sarai Cheryl Hou, Haiguang Ma, Lin Shan, Peiyan Wu, Xinwei |
author_sort | Jia, Guoyong |
collection | PubMed |
description | BACKGROUND: Migraine is the most common primary headache among children and adolescents. The aim of this meta-analysis was to evaluate the efficacy and safety of antiepileptic drugs in the prevention of pediatric migraine. METHODS: PubMed, Cochrane Library, EMBASE and Chinese National Knowledge Infrastructure (CNKI) databases were searched for eligible published RCTs from January 1970 to June 2020. Migraine frequency and ≥50% response rate were measured as the efficacy outcomes. We used “Risk of Bias” tool for quality assessment and RevMan5.3 software for statistical analysis. RESULTS: Four articles containing 7 RCTs with 794 participants compared the efficacy of AEDs with placebo. Four RCTs assessed topiramate vs. placebo and 3 RCTs evaluated divalproex sodium extended-release (DVPX ER) vs. placebo. The results demonstrated that children receiving antiepileptic drugs had a significant advantage in remitting the mean monthly migraine days compared to those who received placebo, with an MD of −0.48 (n=930, 95% CI: −0.84 to −0.12, Z=2.60, P=0.009). Topiramate significantly reduced monthly migraine days (MD =−0.70, n=489, 95% CI: −1.16 to −0.25, Z=3.01, P=0.003) but failed to improve the ≥50% response rate (MD =−1.50, n=489, 95% CI: 0.70 to 3.22, Z=1.05, P=0.30). DVPX ER did not significantly reduce monthly headache frequency (n=441, 95% CI: −0.70 to 0.47, Z=0.38, P=0.70) or improve the ≥50% response rate (n=441, 95% CI: 0.59 to 1.25, Z=0.82, P=0.41) compared with placebo. Topiramate and DVPX ER were related to higher rates of side effects and adverse reactions. DISCUSSION: Topiramate can reduce monthly headache days in children and adolescents with migraine. However, it failed to improve the ≥50% response rate. DVPX ER showed no difference from placebo in the prophylactic treatment pediatric migraine. Side effects seemed to be more frequent in topiramate and DVPX ER treated children but generally well-tolerated. |
format | Online Article Text |
id | pubmed-8349954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-83499542021-08-23 The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials Jia, Guoyong Wang, Xingbang Lv, Hongbo Nonyane, Malebo Sarai Cheryl Hou, Haiguang Ma, Lin Shan, Peiyan Wu, Xinwei Transl Pediatr Original Article BACKGROUND: Migraine is the most common primary headache among children and adolescents. The aim of this meta-analysis was to evaluate the efficacy and safety of antiepileptic drugs in the prevention of pediatric migraine. METHODS: PubMed, Cochrane Library, EMBASE and Chinese National Knowledge Infrastructure (CNKI) databases were searched for eligible published RCTs from January 1970 to June 2020. Migraine frequency and ≥50% response rate were measured as the efficacy outcomes. We used “Risk of Bias” tool for quality assessment and RevMan5.3 software for statistical analysis. RESULTS: Four articles containing 7 RCTs with 794 participants compared the efficacy of AEDs with placebo. Four RCTs assessed topiramate vs. placebo and 3 RCTs evaluated divalproex sodium extended-release (DVPX ER) vs. placebo. The results demonstrated that children receiving antiepileptic drugs had a significant advantage in remitting the mean monthly migraine days compared to those who received placebo, with an MD of −0.48 (n=930, 95% CI: −0.84 to −0.12, Z=2.60, P=0.009). Topiramate significantly reduced monthly migraine days (MD =−0.70, n=489, 95% CI: −1.16 to −0.25, Z=3.01, P=0.003) but failed to improve the ≥50% response rate (MD =−1.50, n=489, 95% CI: 0.70 to 3.22, Z=1.05, P=0.30). DVPX ER did not significantly reduce monthly headache frequency (n=441, 95% CI: −0.70 to 0.47, Z=0.38, P=0.70) or improve the ≥50% response rate (n=441, 95% CI: 0.59 to 1.25, Z=0.82, P=0.41) compared with placebo. Topiramate and DVPX ER were related to higher rates of side effects and adverse reactions. DISCUSSION: Topiramate can reduce monthly headache days in children and adolescents with migraine. However, it failed to improve the ≥50% response rate. DVPX ER showed no difference from placebo in the prophylactic treatment pediatric migraine. Side effects seemed to be more frequent in topiramate and DVPX ER treated children but generally well-tolerated. AME Publishing Company 2021-07 /pmc/articles/PMC8349954/ /pubmed/34430426 http://dx.doi.org/10.21037/tp-20-478 Text en 2021 Translational Pediatrics. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Jia, Guoyong Wang, Xingbang Lv, Hongbo Nonyane, Malebo Sarai Cheryl Hou, Haiguang Ma, Lin Shan, Peiyan Wu, Xinwei The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials |
title | The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials |
title_full | The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials |
title_fullStr | The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials |
title_full_unstemmed | The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials |
title_short | The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials |
title_sort | efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349954/ https://www.ncbi.nlm.nih.gov/pubmed/34430426 http://dx.doi.org/10.21037/tp-20-478 |
work_keys_str_mv | AT jiaguoyong theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT wangxingbang theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT lvhongbo theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT nonyanemalebosaraicheryl theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT houhaiguang theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT malin theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT shanpeiyan theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT wuxinwei theefficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT jiaguoyong efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT wangxingbang efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT lvhongbo efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT nonyanemalebosaraicheryl efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT houhaiguang efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT malin efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT shanpeiyan efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials AT wuxinwei efficacyandsafetyofantiepilepticsintheprophylaxisofpediatricmigrainethemetaanalysisofrandomizedcontrolledtrials |